Ogimoto Aiko, Katsurada Naoko, Yatani Atsuhiko, Mimura Chihiro, Yamamoto Masatsugu, Tachihara Motoko
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
JTO Clin Res Rep. 2023 Nov 25;5(1):100612. doi: 10.1016/j.jtocrr.2023.100612. eCollection 2024 Jan.
HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK-rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK-rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.
HIP1-ALK是ALK重排非小细胞肺癌中一种相对罕见的融合模式。关于ALK酪氨酸激酶抑制剂（TKI）在HIP1-ALK重排肺癌中的耐药机制及治疗策略疗效的现有研究有限。在此，我们报告一例18岁男性HIP1-ALK重排腺癌患者，其在接受ALK TKI治疗后发生BRAF V600E和V1180L突变，BRAF和MEK抑制剂治疗无效。在使用细胞毒性药物化疗后，布加替尼有效。对于ALK重排肺癌罕见变异在获得对ALK TKIs耐药后，开发有效的治疗方法是很有必要的。
